MET · Q2 2025 Earnings
CautiousMetLife
Reported August 6, 2025
30-second summary
Adjusted earnings of $1.36B came in with management openly conceding the quarter "does not demonstrate the full earnings power of MetLife." Adjusted ROE of 14.6% was characterized by management as "well above our cost of capital and very near our mid-teen target range" — ROE itself was in target; the shortfall sat in variable investment income and underwriting. RIS adjusted earnings fell 10% YoY on spread compression, non-medical health ran hot at a 74.8% benefit ratio, and management is again resorting to a late-September pre-announcement on Q3 variable investment income — a forecasting tell. The offset: Asia sales momentum (Japan +10% YTD, Korea +41% YTD), EMEA running above the $70–75M quarterly guide, and the $10B Chariot Re transaction closed on July 1.
Headline numbers
EPS
Q2 FY2025
$2.02
Revenue
Q2 FY2025
$12.75B
-5.9% YoY
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $12.75B | -5.9% |
| EPS | $2.02 | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment performance
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Group Benefits | $6.446B | +3.8% |
| RIS | $1.355B | -47.6% |
| Asia | $1.699B | +1.9% |
| Latin America | $1.634B | +12.1% |
| EMEA | $0.719B | +15.7% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| Adjusted Earnings Available to Common Shareholders | $1,362 million |
| Adjusted Return on Common Stockholders' Equity | 14.6% |
| Adjusted Expense Ratio | 19.3% |
| Book Value Per Common Share | $35.79 |
| Adjusted Book Value Per Common Share | $56.23 |
| Group Life Mortality Ratio | 83.0% |
| Group Non-Medical Health Interest Adjusted Benefit Ratio | 74.8% |
| RIS Annualized General Account Spread | 1.02% |
Management tone
The press release commentary marks a notably more defensive posture than MetLife's typical quarterly framing. Management led with strategy narrative rather than earnings, and the explicit framing that the quarter "does not demonstrate the full earnings power" of the company is unusual — a CFO is rarely asked to ringfence a quarter as unrepresentative unless the underlying numbers compel it.
On earnings power itself. Management's standard posture has been that diversification produces all-weather results each quarter. This quarter introduces a carve-out: "While our earnings power was not fully evident this quarter given the lower than expected variable investment income, we remain confident in delivering all weather performance." The conjunction matters — confidence is now framed forward rather than demonstrated backward.
On underwriting. The shift from "in line with expectations" to "less favorable underwriting, albeit within normal fluctuations" is doing work in both directions. Management is acknowledging the pressure while insisting each individual product remained inside its normal band. The honest admission — "collectively, they had a larger impact this quarter" — is the part that should give investors pause; aggregate stress above the sum of individually normal claim distributions is, by definition, an outlier outcome.
On VII forecasting. "Given the continued difficulty in forecasting VII, we plan to once again disclose preliminary information regarding our Q3 expectations for VII toward the end of September." The phrase "once again" is the tell — this disclosure protocol has been invoked before and is being repeated. Management's confidence in its ability to forecast its largest swing factor is structurally lower than it was a year ago. For a company whose earnings narrative depends on predictability, this is the most important tonal shift in the release.
On RIS spreads. The move from "stable" to acknowledging "less favorable recurring interest margins" with a Q3 guide of stability and a Q4 guide back to "low 100s bps" implicitly concedes that the 1.02% Q2 spread is below the desired run rate. Management is guiding to a recovery they expect but have not yet delivered.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Sunit Kamat · Jefferies
Asked about elevated claims and volatility in Q2 results, and whether management is seeing anything surprising in the non-medical health ratio. Also inquired about Chariot Re outlook and third-party liability deals.
Management stated results are running in line with expectations. Non-medical health ratio pressure is attributable to normal fluctuations in accident, hospital, and critical illness products, not macro factors. Dental business returning to established seasonal patterns with improvements expected in H2. For Chariot Re, management indicated early-stage focus on MetLife-originated liabilities, not third-party liabilities, with $10 billion transaction completed and 'more to come.'
Tom Gallagher · Evercore
Follow-up on non-medical health disability pressure, specifically from high net worth clients. Asked whether pressure is structural (mental nervous claims, employment-related) or temporary. Also inquired about credit reserves for commercial mortgages and RBC impact.
Management identified two specialty long-term clients with injuries resulting in high claim amounts; unrelated to macro factors or other potential causes. Disability represents just above 10% of earned premiums; dental approximately $5 billion. On credit, management noted $200M+ in commercial mortgage reserves anticipated for 2025, indicating orderly loan resolution and normalization; impact of 2-5 RBC points within normal excess capital levels.
Ryan Krueger · KBW
Asked about strong sales growth in Japan and Korea and sustainability outlook. Also inquired about retirement spread stability in H2 2024.
Japan sales up 10% YTD driven by new single premium FX product launched in April and yen strengthening. Korea sales up 41% YTD leveraging U.S. dollar-denominated products from Japan expertise. Rest of Asia up 9% YTD. Management expects to be at top end of Asia sales guidance. On spreads, core spreads expected to remain stable in Q3 with minor seasonality from real estate holdings, reverting to low 100s in Q4.
Wes Carmichael · Autonomous Research
Asked about surrender activity in Japan given yen strengthening and higher JGB yields impact on savings product offering.
Management noted surrenders have come down and persistency back in line with expectations. Yen strengthening is driving lower surrenders, creating short-term underwriting margin headwind but benefiting sales and AUM growth. Higher yen interest rates create favorable macro environment; company has good yen-denominated products (ANH, variable life) and U.S. dollar FX products continue attractive due to rate differential. Management expects to add more yen product offerings.
Jimmy Weller · JP Morgan
Asked whether Q3 optimism on non-medical health improvements is based on cyclical patterns or actual early Q3 results observed. Also asked about Asia earnings being lower than recent quarters despite strong sales.
Management confirmed optimism based on established seasonal patterns in dental (Q3/Q4 favorable) and lack of macro impacts on disability. Specialty high-value claims in disability are single-digit in number with disproportionate impact—not expected to repeat quarterly. No single driver for other non-medical products moving wrong direction; expect normalization. On Asia earnings, lower due to reduced variable investment income (lower PE returns) and less favorable underwriting margin from yen strengthening reducing surrenders. Expects full-year earnings in line with guidance.
What to watch into next quarter
Late-September VII pre-announcement — the level disclosed and the gap vs. Q2's miss will tell investors whether forecasting difficulty is improving or deepening. A second consecutive shortfall would meaningfully damage the all-weather narrative.
Non-medical health benefit ratio — management has staked credibility on a ~200bps improvement to roughly 72.8% in Q3. Anything above 74% would suggest the two-client specialty disability issue is not as isolated as framed.
RIS general account spread — Q3 guided stable near 1.02%, Q4 guided back to "low 100s bps" (i.e. ~1.00–1.05%). Watch whether spread recovery materializes or compresses further as the rate environment evolves.
Chariot Re second transaction — management said "more to come" beyond the initial $10B. Size and timing of the next tranche signals how aggressively capital is being redeployed; near-term these will be MetLife-originated liabilities, not third-party.
Group life mortality ratio — 83.0% in Q2 sits in the target range; management guided "at or slightly below the bottom end" for Q3. A reading meaningfully above 83% would compound the underwriting concerns from non-medical health.
Commercial mortgage credit migration — with >$200M reserves taken and management calling 2025 the peak loss year, watch for incremental reserve build in Q3. A second >$200M quarter would undermine the "peak" framing.
Sources
- MetLife Q2 2025 Quarterly Financial Supplement, SEC filing — https://www.sec.gov/Archives/edgar/data/1099219/000109921925000191/ex992qfsq225.htm
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.